OZ277

Summary

Oz277 (CHEMBL404431) is a phase-3 clinical-stage small molecule; indicated across 1 condition including plasmodium falciparum malaria.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 392.5 Da · C22H36N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL404431
Name	OZ277
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10475633
Molecular formula	C22H36N2O4
Molecular weight	392.5
InChIKey	VXYZBLXGCYNIHP-UHFFFAOYSA-N

SMILES: CC(C)(CNC(=O)CC1CCC2(CC1)OC3(C4CC5CC(C4)CC3C5)OO2)N

Also known as: Oz277, OZ277, Arterolane, NA

Parent form; salt/anhydrous children: CHEMBL570680

Patent coverage: 23 distinct patent families (42 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Plasmodium falciparum malaria	3	MONDO:0005920	EFO:0007444

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).